EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26

Myrsini Ioakeim-Ioannidou, Beow Y Yeap, Zainab O Soetan, Daniel W Kim, Daniel Packard, Rana Hegazy, Engy S Todary, Athena Tejada, Judith Adams, Hanne Kooy, Stephen Zieminski, Nicolas Depauw und 18 weitere

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noaf289 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Myrsini Ioakeim-Ioannidou und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Chondrosarcoma, Spinal Neoplasms, Skull Base Neoplasms, Proton Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To determine if dose escalation improves outcomes for chondrosarcomas (CHS) of the base of the skull (BOS) and the cervical spine (CS).

Methods

A prospective, randomized, dose-escalation trial was designed for patients with CHS of the BOS and CS. Patients were randomly assigned to 70 Gy (RBE) or 76 Gy (RBE). The primary endpoint was local failure (LF). Secondary endpoints included overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and treatment-related toxicities.

Results

Between 1987 and 2007, 105 patients were randomized, median follow-up was 29.2 years (IQR, 26.7-32.4). Forty-six patients were assigned to 70 Gy (RBE) and 59 were assigned to 76 Gy (RBE). LF at 5-, 10-, and 20 years were 7%, 9%, and 11% for 70 Gy (RBE), and 10%, 15%, and 19% for 76 Gy (RBE) (P = .16). Like LF rates, there was no benefit in dose escalation for OS (P = .28) and CSS (P = .22). Progression-free survival at 5-, 10-, and 20 years was 93%, 89%, and 77% for the low-dose group and 83%, 71%, and 59% for the high-dose group (P = .069). Late RT injury ≥ grade 3 was reported in a total of 19 (18%) patients across both dose levels, with 11% in the low-dose group and 24% in the high-dose group (P = .13).

Conclusions

This is the first and largest trial of patients with grade I/II BOS and CS CHS evaluating dose escalation for tumor control. Proton-based RT is effective and safe for these tumors, but there is no apparent benefit in dose escalation. Clinical Trial Information NCT00592748.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChondrosarcomaSpinal NeoplasmsSkull Base NeoplasmsProton TherapyCervical VertebraeHumansFemaleMaleMiddle AgedProspective StudiesAdultFollow-Up StudiesSurvival RateAgedRadiotherapy DosagePrognosis

Stichwörter der Autor:innen

C-spinechondrosarcomalong-term outcomesproton radiationskull base

Autor:innen und Institutionen

  • Department of Radiation Oncology, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Mass General Brigham, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Radiation Oncology, Inova Scholar Cancer Institute, Alexandria, Virginia, USA.
  • Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Radiation Oncology, Children's Cancer Hospital, Cairo, Egypt.
  • St. George's University School of Medicine, True Blue, Grenada (A.T.).

ORCID-Profile: Yin P Hung

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Ioakeim-Ioannidou, M., Yeap, B. Y., Soetan, Z. O., Kim, D. W., Packard, D., Hegazy, R., Todary, E. S., Tejada, A., Adams, J., Kooy, H., Zieminski, S., Depauw, N., Nielsen, G. P., Hung, Y. P., Rosenberg, A., Tobert, D. G., Shankar, G., Curry, W. T., Cote, G. M., …, & MacDonald, S. M. (2026). Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf289

Vancouver

Ioakeim-Ioannidou M, Yeap BY, Soetan ZO, Kim DW, Packard D, Hegazy R, et al. Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf289

BibTeX
@article{IoakeimIoannidou2026,
  author = {Ioakeim-Ioannidou, Myrsini and Yeap, Beow Y and Soetan, Zainab O and Kim, Daniel W and Packard, Daniel and Hegazy, Rana and Todary, Engy S and Tejada, Athena and Adams, Judith and Kooy, Hanne and Zieminski, Stephen and Depauw, Nicolas and Nielsen, Gunnlaugur Petur and Hung, Yin P and Rosenberg, Andrew and Tobert, Daniel G and Shankar, Ganesh and Curry, William T and Cote, Gregory M and Kelly, Hillary R and Cunnane, Mary Elizabeth and Chang, Yuh-Shin and Gardner, Paul and Giap, Fantine and Chen, Yen-Lin and Delaney, Thomas F and Hug, Eugen and Liu, Kevin X and Shih, Helen A and MacDonald, Shannon M},
  title = {Prospective, randomized dose-escalation trial with proton-based radiation for skull base and cervical spine chondrosarcomas: 30-year outcomes from PROG 85-26},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noaf289}
}
Kostenlos starten →